Analyst Consensus ?
ConsensusHold33 ratings
Bullish1236.4%
Neutral1854.5%
Bearish39.1%
Quest Diagnostics Incorporated · DGX · FY2025 Q2 · Calendar Q3 2025
Quest Diagnostics raises guidance as diagnostics demand and M&A drive growth
The supplied analysis supports a constructive operating thesis: resilient demand for advanced diagnostics, consumer testing, and productivity initiatives—alongside acquisitions—could support growth. The main test is whether integration, policy, reimbursement, labor, tariff, and modernization pressures limit margin and volume benefits.
Reported Before market openNYSEHealthcare
$25.22B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.62
Consensus $2.57
EPS surprise
+1.9%
Reported versus consensus
Reported revenue
$2.76B
Consensus $2.73B
Revenue surprise
+1.3%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+7.1%
Event window
SPY move
+0.0%
Same window
Abnormal move
+7.1%
Stock minus SPY
Volume
2.5×
Versus trailing sessions
Subsequent drift
+2.6%
Up to 20 sessions
DGXSPY benchmark
Ask FN2 about DGX FY2025 Q2
Transcript, numbers and history already loaded
Why did DGX rise 7.1% after beating EPS estimates in FY2025 Q2?What changed in DGX's guidance and outlook in FY2025 Q2?Give me the bull and bear case for DGX after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, management's tone remained confident but guidance sentiment moved from maintained to raised. The current analysis places greater emphasis on acquisition contribution, broader automation, and a continued expansion of advanced diagnostic offerings, while retaining policy, reimbursement, labor, tariff, and integration concerns.
Guidance delta
Management raised full-year 2025 revenue and adjusted EPS guidance, according to the supplied transcript analysis.
Key takeaways
- Growth reflected both organic demand for advanced diagnostics and contributions from acquisitions, especially LifeLabs.
- Management highlighted advanced diagnostics, consumer testing, automation, and AI as ongoing growth and productivity priorities.
- Policy-related volume effects and potential PAMA reimbursement pressure remain important watchpoints.
- The company plans broader automation, continued diagnostic-menu expansion, and further accretive acquisitions.
Management priorities
- Expand advanced diagnostic testing across cardiometabolic, brain health, oncology, and related areas.
- Roll out automation and automated accessioning while pursuing productivity gains through AI and the Invigorate program.
- Integrate recent acquisitions and develop additional partnerships and accretive acquisition opportunities.
Follow DGX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$228.39Previous close
$125Low
$197.71Average
$260High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 7, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Hold | Hold | Maintain | Sep 21, 2026 |
| UBS | Neutral | Neutral | Maintain | Sep 8, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 28, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 24, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 24, 2026 |
| Baird | Neutral | Neutral | Maintain | Jul 24, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Apr 8, 2026 |
| Jefferies | Buy | Buy | Maintain | Feb 11, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Feb 10, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Oct 27, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 21, 2025 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 23, 2025 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Dec 17, 2024 |
| B of A Securities | Buy | Buy | Maintain | Dec 13, 2024 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Feb 3, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Jan 25, 2023 |
| Keybanc | Overweight | Overweight | Maintain | Dec 13, 2021 |
| Argus Research | Buy | Hold | Upgrade | Oct 21, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 21, 2020 |
| CFRA | Hold | Strong Buy | Downgrade | Apr 22, 2020 |
| Bank of America | Neutral | Underperform | Upgrade | Dec 19, 2019 |
| Canaccord Genuity | Buy | Buy | Maintain | Jul 24, 2019 |
| Goldman Sachs | Sell | Neutral | Downgrade | Jul 15, 2019 |
| Argus | Hold | Buy | Downgrade | Jan 31, 2019 |
| William Blair | Outperform | Market Perform | Upgrade | Jun 8, 2018 |
| Raymond James | Market Perform | Outperform | Downgrade | Sep 25, 2017 |
| Jyske Bank | Sell | Sell | Maintain | Jun 24, 2016 |
| JMP Securities | Perform | Market Perform | Maintain | Mar 27, 2015 |
| ISI Group | Neutral | Neutral | Maintain | Nov 19, 2013 |
| Craig-Hallum | Buy | Buy | Maintain | Sep 19, 2013 |
| Maxim Group | Buy | Hold | Upgrade | Aug 8, 2013 |
| Oppenheimer | Underperform | Underperform | Maintain | Jan 28, 2013 |
| Macquarie | Neutral | Underperform | Upgrade | Nov 20, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $228.39. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $260 | $246.48 | +13.8% | Sep 21, 2026 |
| UBS | Analyst unavailable | $245 | $235.58 | +7.3% | Sep 8, 2026 |
| Argus Research | Analyst unavailable | $260 | $235.34 | +13.8% | Jul 29, 2026 |
| UBS | Kevin Caliendo | $232 | $231.3 | +1.6% | Jul 24, 2026 |
| Robert W. Baird | Analyst unavailable | $255 | $227.9 | +11.7% | Jul 24, 2026 |
| Barclays | Analyst unavailable | $250 | $227.9 | +9.5% | Jul 23, 2026 |
| Jefferies | Analyst unavailable | $245 | $227.9 | +7.3% | Jul 23, 2026 |
| Robert W. Baird | Analyst unavailable | $236 | $207.44 | +3.3% | Jul 13, 2026 |
| Evercore ISI | Analyst unavailable | $225 | $205.18 | -1.5% | Apr 21, 2026 |
| Jefferies | Analyst unavailable | $225 | $205.18 | -1.5% | Apr 21, 2026 |
| Evercore ISI | Analyst unavailable | $210 | $198.81 | -8.1% | Apr 8, 2026 |
| Mizuho Securities | Analyst unavailable | $235 | $209.32 | +2.9% | Feb 12, 2026 |
| UBS | Analyst unavailable | $210 | $206.72 | -8.1% | Feb 11, 2026 |
| Truist Financial | Analyst unavailable | $220 | $205.62 | -3.7% | Feb 11, 2026 |
| Evercore ISI | Elizabeth Anderson | $220 | $205.43 | -3.7% | Feb 11, 2026 |
| Robert W. Baird | Analyst unavailable | $219 | $205.35 | -4.1% | Feb 11, 2026 |
| Jefferies | Tycho Peterson | $220 | $205.24 | -3.7% | Feb 10, 2026 |
| Barclays | Analyst unavailable | $210 | $182.35 | -8.1% | Jan 30, 2026 |
| Piper Sandler | Analyst unavailable | $200 | $182.18 | -12.4% | Oct 27, 2025 |
| Truist Financial | Analyst unavailable | $205 | $184.64 | -10.2% | Oct 22, 2025 |
| Morgan Stanley | Erin Wright | $207 | $183.18 | -9.4% | Oct 22, 2025 |
| Barclays | Analyst unavailable | $195 | $183.18 | -14.6% | Oct 22, 2025 |
| Jefferies | Analyst unavailable | $215 | $183.34 | -5.9% | Oct 21, 2025 |
| Leerink Partners | Analyst unavailable | $210 | $184.1 | -8.1% | Oct 21, 2025 |
| UBS | Kevin Caliendo | $190 | $186.82 | -16.8% | Oct 17, 2025 |
| Mizuho Securities | Analyst unavailable | $210 | $186.82 | -8.1% | Oct 17, 2025 |
| Truist Financial | Analyst unavailable | $195 | $184 | -14.6% | Oct 14, 2025 |
| Evercore ISI | Analyst unavailable | $190 | $181.89 | -16.8% | Oct 8, 2025 |
| Barclays | Analyst unavailable | $190 | $182.07 | -16.8% | Oct 2, 2025 |
| Robert W. Baird | Analyst unavailable | $194 | $178.66 | -15.1% | Aug 25, 2025 |
| Evercore ISI | Elizabeth Anderson | $185 | $170.48 | -19.0% | Jul 23, 2025 |
| Redburn Partners | Jamie Clark | $195 | $167.96 | -14.6% | Apr 2, 2025 |
| Piper Sandler | David Westenberg | $180 | $162.47 | -21.2% | Feb 3, 2025 |
| Truist Financial | David MacDonald | $182 | $163.1 | -20.3% | Jan 31, 2025 |
| Robert W. Baird | Eric Coldwell | $189 | $163.1 | -17.2% | Jan 31, 2025 |
| Citigroup | Patrick Donnelly | $185 | $157.47 | -19.0% | Oct 23, 2024 |
| Leerink Partners | Michael Cherny | $165 | $157.47 | -27.8% | Oct 23, 2024 |
| Barclays | Stephanie Davis | $168 | $157.47 | -26.4% | Oct 23, 2024 |
| Robert W. Baird | Eric Coldwell | $182 | $157.47 | -20.3% | Oct 23, 2024 |
| CFRA | Paige Meyer | $178 | $157.46 | -22.1% | Oct 22, 2024 |
| Truist Financial | David MacDonald | $165 | $150.79 | -27.8% | Oct 7, 2024 |
| Mizuho Securities | Ann Hynes | $160 | $143.21 | -29.9% | Jul 29, 2024 |
| Robert W. Baird | Eric Coldwell | $154 | $140.96 | -32.6% | Jul 24, 2024 |
| Truist Financial | David MacDonald | $158 | $144.11 | -30.8% | Jul 15, 2024 |
| Barclays | Stephanie Davis | $144 | $137.55 | -36.9% | Apr 25, 2024 |
| Jefferies | Brian Tanquilut | $155 | $127.42 | -32.1% | Feb 7, 2024 |
| Wells Fargo | Analyst unavailable | $140 | $143.29 | -38.7% | Feb 3, 2023 |
| Morgan Stanley | Analyst unavailable | $158 | $155.5 | -30.8% | Jan 6, 2023 |
| Citigroup | Analyst unavailable | $125 | $149.27 | -45.3% | Nov 17, 2022 |
| Morgan Stanley | Analyst unavailable | $142 | $136.13 | -37.8% | May 3, 2022 |
| Wells Fargo | Analyst unavailable | $150 | $133.75 | -34.3% | Apr 25, 2022 |
| Citigroup | Ralph Giacobbe | $175 | $140 | -23.4% | Apr 9, 2022 |
| Deutsche Bank | Pito Chickering | $190 | $142.3 | -16.8% | Jan 15, 2022 |
| KeyBanc | Donald Hooker | $170 | $161.75 | -25.6% | Dec 13, 2021 |
| Credit Suisse | A.J. Rice | $150 | $155.22 | -34.3% | Sep 9, 2021 |
Track every rating change on DGX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationQuest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients.…
Historical context
All DGX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- LWFY2027 Q1 · October 6, 2026+27.8% EPS+7.5% move
- RPMFY2027 Q1 · October 6, 2026+1.5% EPS+3.2% move
- ACNFY2026 Q4 · October 1, 2026+3.5% EPS+15.8% move
- MKCFY2026 Q3 · October 1, 2026+13.9% EPS-4.9% move
- NKEFY2027 Q1 · October 1, 2026+10.0% EPS-0.7% move
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
Get the DGX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
- Polygon adjusted daily market bars · 2026-10-07T07:20:46.115864+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-07T07:20:46.113017+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-07. For educational purposes only; not investment advice.